Search Weight Loss Topics:




Apr 18

Eli Lilly’s Weight-Loss Treatment Found To Help Those With Sleep Apnea – Investopedia

Lose Weight Comments Off on Eli Lilly’s Weight-Loss Treatment Found To Help Those With Sleep Apnea – Investopedia

Key Takeaways

Shares of Eli Lilly (LLY) gained in intraday trading Wednesday after the pharmaceutical firm said a late-stage study found its weight-loss drug, Zepbound, was effective in treating those who are overweight and suffer from obstructive sleep apnea (OSA).

The company said that in a Phase 3 trial, on average, Zepbound reduced by up to 63% the apnea-hypopnea index (AHI) in the test group, achieving all primary and key secondary endpoints. AHI records the number of times a person's breathing shows a restricted or complete block of airflow per hour of sleep, and is used to measure the severity of OSA. Lilly pointed out that at the top end of the findings, use of Zepbound cut the number of events by 30 an hour.

Dr. Jeff Emmick, senior vice president of development at Lilly, explained that OSA affects 80 million adults in the U.S., with more than 20 million having moderate or severe cases. He added that while other drugs for excessive sleeplessness associated with OSA now exist, Zepbound has the potential to be the first pharmaceutical treatment for the underlying disease.

Lilly noted that based on these results, it plans to submit authorization requests for expanded use of Zepbound for OSA to the Food and Drug Administration (FDA) and other global regulatory bodies beginning in the middle of the year.

Zepbound is sold as Mounjaroin some global markets outside theU.S.

Eli Lilly shares rose 0.5% to $750.30 each as of noon ET Wednesday and have added almost 27% so far this year. The news sent shares of ResMed (RMD), which makes devices to treat sleep apnea, down 6% to $173.39.

Continue reading here:
Eli Lilly's Weight-Loss Treatment Found To Help Those With Sleep Apnea - Investopedia

Related Posts

    Your Full Name

    Your Email

    Your Phone Number

    Select your age (30+ only)

    Select Your US State

    Program Choice

    Confirm over 30 years old

    Yes

    Confirm that you resident in USA

    Yes

    This is a Serious Inquiry

    Yes

    Message:



    matomo tracker